This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Dalhousie University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
Canadian Immunization Research Network (CIRN) Renewal
CIHR · 2024 · Co-investigator
- $4,569,190
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
CIHR · 2023 · Co-investigator
- $1,142,297
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
CIHR · 2023 · Co-investigator
Canadian Immunization Research Network (CIRN) Renewal
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Buchan, Sarah; Cowan, Juthaporn; Dubé, Eve; Greyson, Devon; Hatchette, Todd F; Heffernan, Jane M; Kwong, Jeffrey C; Langley, Joanne M; MacDonald, Shannon E; McNeil, Shelly A; Muller, Matthew P; Parsons Leigh, Jeanna J; Sadarangani, Manish; Top, Karina A
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Modeling And Economic Analysis; Vaccine Safety; Vulnerable Populations
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
Canadian Immunization Research Network: COVID-19 Vaccine Readiness
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Dubé, Eve; Hatchette, Todd F; Kellner, James D; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; MacDonald, Shannon E; McNeil, Shelly A; Top, Karina A; Ward, Brian J
Keywords: Adverse Events Following Immunization; Clinical Trials Capacity And Readiness; Immunogenicity; Knowledge Translation; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Hesitancy; Vaccine Modeling; Vaccine Safety And Effectiveness
Canadian Immunization Research Network
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Burchell, Ann N; Coleman, Brenda L; Crowcroft, Natasha S; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Doroshenko, Alexander; Dubé, Eve; Gagneur, Arnaud A; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; McNeil, Shelly A; Sadarangani, Manish; Top, Karina A; Ulanova, Marina; Ward, Brian J
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Modeling And Economic Analysis; Vaccine Safety; Vulnerable Populations
Canadian Immunization Research Network
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Coleman, Brenda L; Crowcroft, Natasha S; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Dubé, Eve; Fisman, David N; Hatchette, Todd F; Isenor, Jennifer; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; MacDougall, Heather A; Mahmud, Salaheddin; McNeil, Shelly A; Naus, Monika; Ogilvie, Gina S; Quach-Thanh, Caroline; Scheifele, David W; Top, Karina A; Van Buynder, Paul; Vaudry, Wendy L; Ward, Brian J; Watts, Tania H; Wilson, Kumanan; Wilson, Sarah
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Safety; Vulnerable Populations
Canadian Immunization Research Network
Principal investigators: Halperin, Scott A; Andrew, Melissa K; Bettinger, Julie A; Bolotin, Shelly; Brisson, Marc; Coleman, Brenda L; Crowcroft, Natasha S; De Serres, Gaston; De Wals, Philippe; Deeks, Shelley L; Dubé, Eve; Hatchette, Todd F; Kwong, Jeffrey C; Langley, Joanne M; Loeb, Mark B; Mahmud, Salaheddin; McNeil, Shelly A; Naus, Monika; Quach-Thanh, Caroline; Scheifele, David W; Skowronski, Danuta Maria; Top, Karina A; Vaudry, Wendy L; Ward, Brian J; Watts, Tania H; Wilson, Kumanan; Wilson, Sarah
Keywords: Adverse Events Following Immunization; Immunogenicity; Population-Based Methodology; Rapid Response Research Capacity; Vaccine Coverage; Vaccine Effectiveness; Vaccine Hesitancy; Vaccine Safety; Vulnerable Populations
PHAC/CIHR Influenza Research Network
Principal investigators: Halperin, Scott A; Bortolussi, Robert A; Collet, Jean-Paul; De Serres, Gaston; Johnson, Marcia M; Kwong, Jeffrey C; McNeil, Shelly A; Scheifele, David W; Ward, Brian J
Keywords: And Effectiveness; Immunogenicity; Influenza; Influenza Vaccine; Pandemic; Vaccine Coverage; Vaccine Program Implementation; Vaccine Safety
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.